Table 4.
Univariate analysis of 5-year OS, DFS, LRRFS, and DMFS in the 180 patients with advanced NPC.
| Characteristic | No.(%) | 5-year OS (%) | p value | 5-year DFS (%) | p value | 5-year LFFRS (%) | p value | 5-year DMFS (%) | p value |
|---|---|---|---|---|---|---|---|---|---|
| Sex | 0.749 | 0.782 | 0.449 | 0.522 | |||||
| Male | 114 (63.3) | 86.8 | 89.5 | 96.4 | 91.2 | ||||
| Female | 66 (36.7) | 89.4 | 87.9 | 90.9 | 93.9 | ||||
| Age (years) | 0.823 | 0.678 | 0.665 | 0.066 | |||||
| <45 | 84 (46.7) | 89.3 | 86.9 | 96.4 | 88.1 | ||||
| ≥45 | 96 (53.3) | 86.4 | 90.6 | 94.8 | 95.8 | ||||
| T category | 0.371 | 0.095 | 0.251 | 0.045 | |||||
| T1-2 | 38 (21.1) | 84.2 | 81.6 | 92.1 | 84.2 | ||||
| T3-4 | 142 (78.9) | 88.7 | 90.2 | 96.5 | 94.3 | ||||
| N category | 0.137 | 0.169 | 0.794 | 0.035 | |||||
| N0-1 | 80 (44.4) | 91.3 | 92.5 | 95.0 | 97.5 | ||||
| N2-3 | 100 (55.6) | 85.0 | 86.0 | 96.0 | 88.0 | ||||
| KPS | 0.349 | 0.628 | 0.403 | 0.164 | |||||
| <90 | 44 (24.4) | 84.1 | 90.9 | 93.2 | 97.7 | ||||
| ≥90 | 136 (75.6) | 88.9 | 88.2 | 96.3 | 90.4 | ||||
| Cisplatin regimen | 0.207 | 0.152 | 0.411 | 0.107 | |||||
| Weekly cisplatin | 90 (50.0) | 85.6 | 85.6 | 94.4 | 88.9 | ||||
| 3-weekly cisplatin | 90 (50.0) | 90.0 | 92.2 | 96.7 | 95.6 | ||||
| EBV DNA (copies/ml) | 0.016 | 0.010 | 0.026 | 0.198 | |||||
| <1000 | 105 (58.3) | 93.3 | 94.3 | 99.0 | 94.3 | ||||
| ≥1000 | 75 (41.7) | 80 | 81.3 | 90.7 | 89.3 |
p values were calculated by using the log-rank test. T and N categories are according to the 6th edition of the International Union Against Cancer/American Joint Commission on Cancer staging system.
Abbreviations: DFS, disease-free survival; DMFS, distant metastasis-free survival; IMRT, intensity-modulated radiotherapy; KPS, Karnofsky performance score; LRRFS, locoregional relapse-free survival; NPC, nasopharyngeal carcinoma; OS, overall survival; RT, radiotherapy.